[1]张炜浩,郭 志,李保国,等.CT导向下125I粒子植入补救治疗盆腔恶性肿瘤近期疗效评价[J].介入放射学杂志,2013,(04):308-311.
 ZHANG Wei? hao,GUO Zhi,LI Bao? guo,et al.CT- guided radioactive seeds 125I implantation used as salvage therapy for malignant pelvic tumors: evaluation of short- term effects[J].journal interventional radiology,2013,(04):308-311.
点击复制

CT导向下125I粒子植入补救治疗盆腔恶性肿瘤近期疗效评价()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年04期
页码:
308-311
栏目:
非血管介入
出版日期:
2013-04-17

文章信息/Info

Title:
CT- guided radioactive seeds 125I implantation used as salvage therapy for malignant pelvic tumors: evaluation of short- term effects
作者:
张炜浩 郭 志 李保国 于海鹏 司同国 倪 虹 姚艳红
Author(s):
ZHANG Wei?蛳 hao GUO Zhi LI Bao?蛳 guo YU Hai?蛳 peng SI Tong?蛳 guo NI Hong YAO Yan?蛳 hong.
Department of Interventional Therapy, Affiliated Tumor Hospital of Tianjin Medical University, Tianjin Municipal Key Laboratory of Cancer Prevention and Treatment, Tianjin 300060, China
关键词:
【关键词】 盆腔恶性肿瘤 补救治疗 125I粒子 近期疗效
文献标志码:
A
摘要:
【摘要】 目的 评价CT导向下125I粒子植入补救治疗盆腔恶性肿瘤的近期临床疗效及安全性。方法 32例盆腔恶性肿瘤,可评价病灶35处,肿瘤长径为3 ~ 12 cm,平均(6.8 ± 2.3)cm。所有病例均为接受过手术、化疗或放疗等综合治疗后盆腔复发或转移的恶性肿瘤患者,术前应用治疗计划系统(TPS)计算布源,在CT导向下将125I粒子植入盆腔病灶内,随访观察临床受益率、疼痛缓解率、生活质量评分及并发症状况。结果 术后随访2个月,随访结束评价病灶完全缓解(CR)4/35,部分缓解(PR)20/35,病灶稳定(SD)6/35,病灶进展(PD)5/35,临床受益率(CR + PR + SD)85.7%(30/35),疼痛缓解率89.3%(25/28),总体生活质量较治疗前有明显改善(P < 0.001)。近期不良反应轻微,未见大出血、盆腔脓肿、肠瘘、肠穿孔等严重并发症。结论 CT导向下125I粒子植入补救治疗盆腔恶性肿瘤安全有效、操作简便、创伤小、近期临床受益率高,可作为一种改善患者生活质量、降低肿瘤负荷的高效局部治疗手段。

参考文献/References:

[1] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228 ?蛳 247.[2] Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of Life measurement system[J]. Qual Life Res, 1996, 5: 309 ?蛳 320.[3] Chase DM, Huang HQ, Wenzel L, et al. Quality of Life and survival in advanced cervical Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2012, 125: 315 ?蛳 319.[4] Bouchard P, Efron J. Management of recurrent rectal cancer[J]. Ann Surg Oncol, 2010, 17: 1343 ?蛳 1356.[5] 范卫君, 张 亮, 张福君, 等. CT导向下125I粒子植入治疗复发性盆腔恶性肿瘤[J]. 中国微创外科杂志, 2007, 7: 127 ?蛳 129.[6] Park RI, Liberman FZ, Lee DJ, et al. Iodine?蛳 125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell Cancer of the head and neck[J]. Laryngoscope, 1991, 101: 405 ?蛳 410.[7] Cosset JM, Flam T, Thiounn N, et al. Brachytherapy for prostate Cancer: old concept, new techniques[J]. Bull Cancer, 2006, 93: 761 ?蛳 766.[8] Wang J, Jiang Y, Li J, et al. Intraoperative ultrasound?蛳 guided iodine?蛳 125 seed implantation for unresectable pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2009, 28: 88.[9] Nag S, Dehaan M, Scruggs G, et al. Long?蛳 term follow?蛳 up of patients of intrahepatic malignancies treated with iodine?蛳 125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2006, 64: 736 ?蛳 744.[10] Sharma SK, Forgione H, Isaacs JH. Iodine?蛳 125 interstitial implants as salvage therapy for recurrent gynecologic malignancies[J]. Cancer, 1991, 67: 2467 ?蛳 2471.[11] Wang Z, Lu J, Liu L, et al. Clinical application of CT?蛳 guided (125)I seed interstitial implantation for local recurrent rectal carcinoma[J]. Radiat Oncol, 2011, 6: 138.[12] Wang JJ, Yuan HS, Li JN, et al. CT?蛳 guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy[J]. Med Oncol, 2010, 27: 421 ?蛳 429.[13] Van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review[J]. Radiother Oncol, 2011, 98: 287 ?蛳 291.[14] Stone NN, Stock RG. Long?蛳 term urinary, sexual, and rectal morbidity in patients treated with iodine?蛳 125 prostate brachytherapy followed up for a minimum of 5 years[J]. Urology, 2007, 69: 338 ?蛳 342.

备注/Memo

备注/Memo:
(收稿日期:2012-11-30)
更新日期/Last Update: